Serum Nogo-A levels are not elevated in amyotrophic lateral sclerosis patients
Serum Nogo-A levels are not elevated in amyotrophic lateral sclerosis patients
复制标题
DOI：
10.1080/13547500903056051
复制
发表时间：
2009-01-01
期刊：
影响因子：
2.6
通讯作者：
Strittmatter, Stephen M.
中科院分区：
文献类型：
--
作者：
Harel, Noam Y.;Cudkowicz, Merit E.;Strittmatter, Stephen M.
改进的生物标志物将有助于肌萎缩侧索硬化症（ALS）的诊断和治疗。肌萎缩侧索硬化症和其他去神经支配疾病患者的神经炎生长抑制剂Nogo-A的肌肉含量增加。为了寻求一种侵入性较小的诊断方法，我们试图确定ALS患者血清中Nogo是否增加。我们开发了一种解离增强的镧系元素荧光免疫测定（DELFIA）方案，以筛选172名ALS患者和172名健康对照的Nogo-A免疫反应性血清样本。出乎意料的是，在ALS中存在血清Nogo-A水平降低的趋势。ALS患者的平均血清Nogo-A水平为0.71 nM（95%置信区间（CI）0.42-1.00），而健康对照组为1.15 nM（95% CI 0.72-1.59）。健康对照血清的显著更大百分比（11.0%对4.7%）显示Nogo-A水平显著升高。需要进一步的研究来确定导致ALS患者和健康对照组中Nogo-A水平升高的因素。
Improved biomarkers would facilitate the diagnosis and treatment of amyotrophic lateral sclerosis (ALS). Muscle content of the neuritic outgrowth inhibitor Nogo-A is increased in patients with ALS and other denervating conditions. Seeking a less invasive diagnostic method, we sought to determine whether or not Nogo increases in the serum of ALS patients. We developed a dissociation-enhanced lanthanide fluorescent immunoassay (DELFIA) protocol to screen serum samples from 172 ALS patients and 172 healthy controls for Nogo-A immunoreactivity. Unexpectedly, there was a trend toward decreased levels of serum Nogo-A in ALS. Mean serum Nogo-A level in ALS patients was 0.71 nM (95% confidence interval (CI) 0.42-1.00), as opposed to 1.15 nM (95% CI 0.72-1.59) in healthy controls. A significantly larger percentage of healthy control sera (11.0% vs 4.7%) displayed markedly elevated levels of Nogo-A. Additional study is required to determine the factors that lead to elevated Nogo-A levels in a subset of both ALS patients and healthy controls.